PIK3CA mutation
|
HER2 Negative Breast Cancer
|
PIK3CA mutation
|
HER2 Negative Breast Cancer
|
alpelisib Sensitive: B - Late Trials
|
alpelisib Sensitive: B - Late Trials
|
PIK3CA mutation
|
Breast Cancer
|
PIK3CA mutation
|
Breast Cancer
|
BKM120 Sensitive: B - Late Trials
|
BKM120 Sensitive: B - Late Trials
|
PIK3CA mutation
|
Breast Cancer
|
PIK3CA mutation
|
Breast Cancer
|
alpelisib Sensitive: B - Late Trials
|
alpelisib Sensitive: B - Late Trials
|
PIK3CA mutation
|
Triple Negative Breast Cancer
|
PIK3CA mutation
|
Triple Negative Breast Cancer
|
RG7440 Sensitive: B - Late Trials
|
RG7440 Sensitive: B - Late Trials
|
PIK3CA mutation
|
CRC
|
PIK3CA mutation
|
CRC
|
panitumumab Resistant: B - Late Trials
|
panitumumab Resistant: B - Late Trials
|
PIK3CA mutation
|
HER2 Positive Breast Cancer
|
PIK3CA mutation
|
HER2 Positive Breast Cancer
|
neratinib Resistant: B - Late Trials
|
neratinib Resistant: B - Late Trials
|
PIK3CA mutation
|
HER2 Positive Breast Cancer
|
PIK3CA mutation
|
HER2 Positive Breast Cancer
|
lapatinib Resistant: B - Late Trials
|
lapatinib Resistant: B - Late Trials
|
PIK3CA mutation
|
HER2 Positive Breast Cancer
|
PIK3CA mutation
|
HER2 Positive Breast Cancer
|
trastuzumab Resistant: B - Late Trials
|
trastuzumab Resistant: B - Late Trials
|
PIK3CA mutation
|
CRC
|
PIK3CA mutation
|
CRC
|
atezolizumab + cobimetinib Sensitive: B - Late Trials
|
atezolizumab + cobimetinib Sensitive: B - Late Trials
|
PIK3CA mutation
|
HER2 Positive Breast Cancer
|
PIK3CA mutation
|
HER2 Positive Breast Cancer
|
everolimus Sensitive: B - Late Trials
|
everolimus Sensitive: B - Late Trials
|
PIK3CA mutation
|
NSCLC
|
PIK3CA mutation
|
NSCLC
|
erlotinib Resistant: B - Late Trials
|
erlotinib Resistant: B - Late Trials
|
PIK3CA mutation
|
Urothelial Cancer
|
PIK3CA mutation
|
Urothelial Cancer
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
PIK3CA mutation
|
Gastric Cancer
|
PIK3CA mutation
|
Gastric Cancer
|
alpelisib Sensitive: C2 – Inclusion Criteria
|
alpelisib Sensitive: C2 – Inclusion Criteria
|
PIK3CA mutation
|
HER2 Positive Breast Cancer
|
PIK3CA mutation
|
HER2 Positive Breast Cancer
|
trastuzumab + MEN1611 Sensitive: C2 – Inclusion Criteria
|
trastuzumab + MEN1611 Sensitive: C2 – Inclusion Criteria
|
PIK3CA mutation
|
Uterine Cancer
|
PIK3CA mutation
|
Uterine Cancer
|
copanlisib Sensitive: C2 – Inclusion Criteria
|
copanlisib Sensitive: C2 – Inclusion Criteria
|
PIK3CA mutation
|
HER2 Positive Breast Cancer
|
PIK3CA mutation
|
HER2 Positive Breast Cancer
|
MEN1611 Sensitive: C2 – Inclusion Criteria
|
MEN1611 Sensitive: C2 – Inclusion Criteria
|
PIK3CA mutation
|
Breast Cancer
|
PIK3CA mutation
|
Breast Cancer
|
palbociclib Sensitive: C2 – Inclusion Criteria
|
palbociclib Sensitive: C2 – Inclusion Criteria
|
PIK3CA mutation
|
Ovarian Cancer
|
PIK3CA mutation
|
Ovarian Cancer
|
CYH33 Sensitive: C2 – Inclusion Criteria
|
CYH33 Sensitive: C2 – Inclusion Criteria
|
PIK3CA mutation
|
Breast Cancer
|
PIK3CA mutation
|
Breast Cancer
|
MEN1611 Sensitive: C2 – Inclusion Criteria
|
MEN1611 Sensitive: C2 – Inclusion Criteria
|
PIK3CA mutation
|
Breast Cancer
|
PIK3CA mutation
|
Breast Cancer
|
CYH33 Sensitive: C2 – Inclusion Criteria
|
CYH33 Sensitive: C2 – Inclusion Criteria
|
PIK3CA mutation
|
Breast Cancer
|
PIK3CA mutation
|
Breast Cancer
|
GDC-0032 Sensitive: C2 – Inclusion Criteria
|
GDC-0032 Sensitive: C2 – Inclusion Criteria
|
PIK3CA mutation
|
Gastric Cancer
|
PIK3CA mutation
|
Gastric Cancer
|
AZD5363 Sensitive: C2 – Inclusion Criteria
|
AZD5363 Sensitive: C2 – Inclusion Criteria
|
PIK3CA mutation
|
SCCHN
|
PIK3CA mutation
|
SCCHN
|
alpelisib Sensitive: C2 – Inclusion Criteria
|
alpelisib Sensitive: C2 – Inclusion Criteria
|
PIK3CA mutation
|
Hormone Receptor Positive Breast Cancer
|
PIK3CA mutation
|
Hormone Receptor Positive Breast Cancer
|
alpelisib Sensitive: C2 – Inclusion Criteria
|
alpelisib Sensitive: C2 – Inclusion Criteria
|
PIK3CA mutation
|
Solid Tumor
|
PIK3CA mutation
|
Solid Tumor
|
copanlisib Sensitive: C2 – Inclusion Criteria
|
copanlisib Sensitive: C2 – Inclusion Criteria
|
PIK3CA mutation
|
NSCLC
|
PIK3CA mutation
|
NSCLC
|
U3-1402 Sensitive: C3 – Early Trials
|
U3-1402 Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
Triple Negative Breast Cancer
|
PIK3CA mutation
|
Triple Negative Breast Cancer
|
everolimus Sensitive: C3 – Early Trials
|
everolimus Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
SCCHN
|
PIK3CA mutation
|
SCCHN
|
temsirolimus Sensitive: C3 – Early Trials
|
temsirolimus Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
NSCLC
|
PIK3CA mutation
|
NSCLC
|
ensartinib Resistant: C3 – Early Trials
|
ensartinib Resistant: C3 – Early Trials
|
PIK3CA mutation
|
Breast Cancer
|
PIK3CA mutation
|
Breast Cancer
|
bevacizumab Sensitive: C3 – Early Trials
|
bevacizumab Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
Breast Cancer
|
PIK3CA mutation
|
Breast Cancer
|
ribociclib Sensitive: C3 – Early Trials
|
ribociclib Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
Hormone Receptor Positive Breast Cancer
|
PIK3CA mutation
|
Hormone Receptor Positive Breast Cancer
|
fulvestrant + anastrozole Sensitive: C3 – Early Trials
|
fulvestrant + anastrozole Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
Breast Cancer
|
PIK3CA mutation
|
Breast Cancer
|
CDK6 inhibitor Resistant: C3 – Early Trials
|
CDK6 inhibitor Resistant: C3 – Early Trials
|
PIK3CA mutation
|
Breast Cancer
|
PIK3CA mutation
|
Breast Cancer
|
CDK4 inhibitor Resistant: C3 – Early Trials
|
CDK4 inhibitor Resistant: C3 – Early Trials
|
PIK3CA mutation
|
Liposarcoma
|
PIK3CA mutation
|
Liposarcoma
|
copanlisib Sensitive: C3 – Early Trials
|
copanlisib Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
NSCLC
|
PIK3CA mutation
|
NSCLC
|
osimertinib Resistant: C3 – Early Trials
|
osimertinib Resistant: C3 – Early Trials
|
PIK3CA mutation
|
Estrogen Receptor Positive Breast Cancer
|
PIK3CA mutation
|
Estrogen Receptor Positive Breast Cancer
|
letrozole Sensitive: C3 – Early Trials
|
letrozole Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
CRC
|
PIK3CA mutation
|
CRC
|
trametinib + dabrafenib Sensitive: C3 – Early Trials
|
trametinib + dabrafenib Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
Head and Neck Cancer
|
PIK3CA mutation
|
Head and Neck Cancer
|
GDC-0032 Sensitive: C3 – Early Trials
|
GDC-0032 Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
Gastric Cancer
|
PIK3CA mutation
|
Gastric Cancer
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
SCCHN
|
PIK3CA mutation
|
SCCHN
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
PIK3CA mutation
|
Lung Non-Small Cell Squamous Cancer
|
PIK3CA mutation
|
Lung Non-Small Cell Squamous Cancer
|
GDC-0032 Sensitive: C3 – Early Trials
|
GDC-0032 Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
SCCHN
|
PIK3CA mutation
|
SCCHN
|
cetuximab + alpelisib Sensitive: C3 – Early Trials
|
cetuximab + alpelisib Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
Breast Cancer
|
PIK3CA mutation
|
Breast Cancer
|
trastuzumab Resistant: C3 – Early Trials
|
trastuzumab Resistant: C3 – Early Trials
|
PIK3CA mutation
|
CRC
|
PIK3CA mutation
|
CRC
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
PIK3CA mutation
|
Solid Tumor
|
PIK3CA mutation
|
Solid Tumor
|
LY2606368 + LY3023414 Sensitive: C3 – Early Trials
|
LY2606368 + LY3023414 Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
HER2 Positive Breast Cancer
|
PIK3CA mutation
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Resistant: C3 – Early Trials
|
ado-trastuzumab emtansine Resistant: C3 – Early Trials
|
PIK3CA mutation
|
Hormone Receptor Positive Breast Cancer
|
PIK3CA mutation
|
Hormone Receptor Positive Breast Cancer
|
everolimus + exemestane Sensitive: C3 – Early Trials
|
everolimus + exemestane Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
CRC
|
PIK3CA mutation
|
CRC
|
FOLFOX Resistant: C3 – Early Trials
|
FOLFOX Resistant: C3 – Early Trials
|
PIK3CA mutation
|
CRC
|
PIK3CA mutation
|
CRC
|
CAPOX Resistant: C3 – Early Trials
|
CAPOX Resistant: C3 – Early Trials
|
PIK3CA mutation
|
HER2 Positive Breast Cancer
|
PIK3CA mutation
|
HER2 Positive Breast Cancer
|
trastuzumab + alpelisib + LJM-716 Sensitive: C3 – Early Trials
|
trastuzumab + alpelisib + LJM-716 Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
Cervical Cancer
|
PIK3CA mutation
|
Cervical Cancer
|
anlotinib + sintilimab Sensitive: C3 – Early Trials
|
anlotinib + sintilimab Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
NSCLC
|
PIK3CA mutation
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
Pancreatic Ductal Adenocarcinoma
|
PIK3CA mutation
|
Pancreatic Ductal Adenocarcinoma
|
avelumab + binimetinib Sensitive: C3 – Early Trials
|
avelumab + binimetinib Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
Triple Negative Breast Cancer
|
PIK3CA mutation
|
Triple Negative Breast Cancer
|
cisplatin + paclitaxel Resistant: C3 – Early Trials
|
cisplatin + paclitaxel Resistant: C3 – Early Trials
|
PIK3CA mutation
|
Cervical Cancer
|
PIK3CA mutation
|
Cervical Cancer
|
alpelisib Sensitive: C3 – Early Trials
|
alpelisib Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
Breast Cancer
|
PIK3CA mutation
|
Breast Cancer
|
docetaxel + cyclophosphamide + eribulin mesylate Resistant: C3 – Early Trials
|
docetaxel + cyclophosphamide + eribulin mesylate Resistant: C3 – Early Trials
|
PIK3CA mutation
|
NSCLC
|
PIK3CA mutation
|
NSCLC
|
alpelisib Sensitive: C4 – Case Studies
|
alpelisib Sensitive: C4 – Case Studies
|
PIK3CA mutation
|
Ampulla of Vater Carcinoma
|
PIK3CA mutation
|
Ampulla of Vater Carcinoma
|
everolimus Sensitive: C4 – Case Studies
|
everolimus Sensitive: C4 – Case Studies
|
PIK3CA mutation
|
Breast Cancer
|
PIK3CA mutation
|
Breast Cancer
|
PP242 Sensitive: D – Preclinical
|
PP242 Sensitive: D – Preclinical
|
PIK3CA mutation
|
Triple Negative Breast Cancer
|
PIK3CA mutation
|
Triple Negative Breast Cancer
|
crizotinib + sunitinib Sensitive: D – Preclinical
|
crizotinib + sunitinib Sensitive: D – Preclinical
|
PIK3CA mutation
|
Triple Negative Breast Cancer
|
PIK3CA mutation
|
Triple Negative Breast Cancer
|
gefitinib + everolimus Sensitive: D – Preclinical
|
gefitinib + everolimus Sensitive: D – Preclinical
|
PIK3CA mutation
|
NSCLC
|
PIK3CA mutation
|
NSCLC
|
GDC-0941 Sensitive: D – Preclinical
|
GDC-0941 Sensitive: D – Preclinical
|
PIK3CA mutation
|
Estrogen Receptor Positive Breast Cancer
|
PIK3CA mutation
|
Estrogen Receptor Positive Breast Cancer
|
ribociclib + VRx-510 Sensitive: D – Preclinical
|
ribociclib + VRx-510 Sensitive: D – Preclinical
|
PIK3CA mutation
|
Estrogen Receptor Positive Breast Cancer
|
PIK3CA mutation
|
Estrogen Receptor Positive Breast Cancer
|
palbociclib + VRx-510 Sensitive: D – Preclinical
|
palbociclib + VRx-510 Sensitive: D – Preclinical
|
PIK3CA mutation
|
HER2 Positive Breast Cancer
|
PIK3CA mutation
|
HER2 Positive Breast Cancer
|
CCT128930 Sensitive: D – Preclinical
|
CCT128930 Sensitive: D – Preclinical
|
PIK3CA mutation
|
Ovarian Cancer
|
PIK3CA mutation
|
Ovarian Cancer
|
AVTX-006 Sensitive: D – Preclinical
|
AVTX-006 Sensitive: D – Preclinical
|
PIK3CA mutation
|
Breast Cancer
|
PIK3CA mutation
|
Breast Cancer
|
CB-228 Sensitive: D – Preclinical
|
CB-228 Sensitive: D – Preclinical
|
PIK3CA mutation
|
Colon Cancer
|
PIK3CA mutation
|
Colon Cancer
|
PF-05212384 + PD-0325901 Sensitive: D – Preclinical
|
PF-05212384 + PD-0325901 Sensitive: D – Preclinical
|
PIK3CA mutation
|
Thyroid Gland Carcinoma
|
PIK3CA mutation
|
Thyroid Gland Carcinoma
|
temsirolimus + MK-2206 Sensitive: D – Preclinical
|
temsirolimus + MK-2206 Sensitive: D – Preclinical
|
PIK3CA mutation
|
Endometrial Cancer
|
PIK3CA mutation
|
Endometrial Cancer
|
temsirolimus Sensitive: D – Preclinical
|
temsirolimus Sensitive: D – Preclinical
|
PIK3CA mutation
|
Endometrial Cancer
|
PIK3CA mutation
|
Endometrial Cancer
|
GDC-0941 Sensitive: D – Preclinical
|
GDC-0941 Sensitive: D – Preclinical
|
PIK3CA mutation
|
Endometrial Cancer
|
PIK3CA mutation
|
Endometrial Cancer
|
RTB101 Sensitive: D – Preclinical
|
RTB101 Sensitive: D – Preclinical
|
PIK3CA mutation
|
Head and Neck Cancer
|
PIK3CA mutation
|
Head and Neck Cancer
|
celecoxib Sensitive: D – Preclinical
|
celecoxib Sensitive: D – Preclinical
|
PIK3CA mutation
|
Breast Cancer
|
PIK3CA mutation
|
Breast Cancer
|
trastuzumab + MEN1611 Sensitive: D – Preclinical
|
trastuzumab + MEN1611 Sensitive: D – Preclinical
|
PIK3CA mutation
|
Thyroid Gland Carcinoma
|
PIK3CA mutation
|
Thyroid Gland Carcinoma
|
MK-2206 Sensitive: D – Preclinical
|
MK-2206 Sensitive: D – Preclinical
|
PIK3CA mutation
|
SCCHN
|
PIK3CA mutation
|
SCCHN
|
tipifarnib Sensitive: D – Preclinical
|
tipifarnib Sensitive: D – Preclinical
|
PIK3CA mutation
|
SCCHN
|
PIK3CA mutation
|
SCCHN
|
cetuximab + AZD8055 Sensitive: D – Preclinical
|
cetuximab + AZD8055 Sensitive: D – Preclinical
|
PIK3CA mutation
|
SCCHN
|
PIK3CA mutation
|
SCCHN
|
GDC-0032 Sensitive: D – Preclinical
|
GDC-0032 Sensitive: D – Preclinical
|
PIK3CA mutation
|
Melanoma
|
PIK3CA mutation
|
Melanoma
|
vemurafenib Resistant: D – Preclinical
|
vemurafenib Resistant: D – Preclinical
|
PIK3CA mutation
|
Breast Cancer
|
PIK3CA mutation
|
Breast Cancer
|
alpelisib + abemaciclib Sensitive: D – Preclinical
|
alpelisib + abemaciclib Sensitive: D – Preclinical
|
PIK3CA mutation
|
Cervical Cancer
|
PIK3CA mutation
|
Cervical Cancer
|
neratinib + copanlisib Sensitive: D – Preclinical
|
neratinib + copanlisib Sensitive: D – Preclinical
|
PIK3CA mutation
|
Breast Cancer
|
PIK3CA mutation
|
Breast Cancer
|
mTORC1 inhibitor Sensitive: D – Preclinical
|
mTORC1 inhibitor Sensitive: D – Preclinical
|
PIK3CA mutation
|
Triple Negative Breast Cancer
|
PIK3CA mutation
|
Triple Negative Breast Cancer
|
epirubicin Resistant: D – Preclinical
|
epirubicin Resistant: D – Preclinical
|
PIK3CA mutation
|
Endometrial Cancer
|
PIK3CA mutation
|
Endometrial Cancer
|
RG7440 Sensitive: D – Preclinical
|
RG7440 Sensitive: D – Preclinical
|
PIK3CA mutation
|
Adenoid Cystic Carcinoma
|
PIK3CA mutation
|
Adenoid Cystic Carcinoma
|
PI3K inhibitor Sensitive: D – Preclinical
|
PI3K inhibitor Sensitive: D – Preclinical
|
PIK3CA mutation
|
Endometrial Cancer
|
PIK3CA mutation
|
Endometrial Cancer
|
LY3023414 Sensitive: D – Preclinical
|
LY3023414 Sensitive: D – Preclinical
|
PIK3CA mutation
|
CRC
|
PIK3CA mutation
|
CRC
|
alpelisib + ribociclib Sensitive: D – Preclinical
|
alpelisib + ribociclib Sensitive: D – Preclinical
|
PIK3CA mutation
|
Lung Cancer
|
PIK3CA mutation
|
Lung Cancer
|
EZH2 inhibitor Sensitive: D – Preclinical
|
EZH2 inhibitor Sensitive: D – Preclinical
|
PIK3CA mutation
|
Lung Cancer
|
PIK3CA mutation
|
Lung Cancer
|
PI3K inhibitor + EZH2 inhibitor Sensitive: D – Preclinical
|
PI3K inhibitor + EZH2 inhibitor Sensitive: D – Preclinical
|
PIK3CA mutation
|
SCCHN
|
PIK3CA mutation
|
SCCHN
|
alpelisib + tipifarnib Sensitive: D – Preclinical
|
alpelisib + tipifarnib Sensitive: D – Preclinical
|